# Allogene Therapeutics, Inc.: overview ALLO · Nasdaq · CIK 1737287 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/allo.md) · [Financials](/companies/allo/financials.md) · [Filings](/companies/allo/filings.md) · [Insiders](/companies/allo/insiders.md) Latest reported revenue: [$4.6m](/filings/0001628280-26-056213.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-056213). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001628280-25-050230.md) | [0.0 d](/filings/0001628280-26-017242.md) | [0.0](/filings/0001737287-25-000064.md) | [0.0](/filings/0001628280-26-056213.md) | [0.0](/filings/0001628280-25-050230.md) | [0.0 d](/filings/0001628280-26-017242.md) | not reported | [4.6](/filings/0001628280-26-056213.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(1011.2%)](/filings/0001628280-26-056213.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(919.8%)](/filings/0001628280-26-056213.md) | | Diluted EPS | $ per share | [(0.32)](/filings/0001628280-25-050230.md) | not reported | [(0.28)](/filings/0001628280-26-034585.md) | [(0.23)](/filings/0001628280-26-056213.md) | [(0.19)](/filings/0001628280-25-050230.md) | not reported | [(0.18)](/filings/0001628280-26-034585.md) | [(0.13)](/filings/0001628280-26-056213.md) | | Free cash flow | $m | [(44.5) d](/filings/0001628280-25-050230.md) | [(37.0) d](/filings/0001628280-26-017242.md) | [(53.0)](/filings/0001628280-26-034585.md) | [(39.1) d](/filings/0001628280-26-056213.md) | [(29.9) d](/filings/0001628280-25-050230.md) | [(27.6) d](/filings/0001628280-26-017242.md) | [(12.9)](/filings/0001628280-26-034585.md) | [(32.1) d](/filings/0001628280-26-056213.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [114](/filings/0001737287-24-000021.md) | [0.2](/filings/0001737287-24-000021.md) | [0.1](/filings/0001737287-25-000036.md) | [0.0](/filings/0001628280-26-017242.md) | [0.0](/filings/0001628280-26-017242.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(157.9%)](/filings/0001737287-24-000021.md) | [(215087.2%)](/filings/0001737287-24-000021.md) | [(344986.3%)](/filings/0001737287-25-000036.md) | [(1241813.6%)](/filings/0001628280-26-017242.md) | not reported | | Net margin | % | [(159.6%)](/filings/0001737287-24-000021.md) | [(218214.1%)](/filings/0001737287-24-000021.md) | [(344489.5%)](/filings/0001737287-25-000036.md) | [(1170863.6%)](/filings/0001628280-26-017242.md) | not reported | | Diluted EPS | $ per share | [(1.34)](/filings/0001737287-24-000021.md) | [(2.38)](/filings/0001737287-24-000021.md) | [(2.09)](/filings/0001737287-25-000036.md) | [(1.32)](/filings/0001628280-26-017242.md) | [(0.87)](/filings/0001628280-26-017242.md) | | Free cash flow | $m | [(206)](/filings/0001737287-24-000021.md) | [(226)](/filings/0001737287-24-000021.md) | [(239)](/filings/0001737287-25-000036.md) | [(201)](/filings/0001628280-26-017242.md) | [(150)](/filings/0001628280-26-017242.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/allo/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-21 | [Parker Geoffrey M.](/insiders/1491874.md) | CHIEF FINANCIAL OFFICER, Officer | Sale (S) | 36,342 | $1.34 | $48.7k | [Form 4](/filings/0001491874-26-000005.md) | | 2018-10-15 | [Pfizer Inc](/insiders/78003.md) | 10% owner | Purchase (P) | 55,556 | $18.00 | $1.0m | [Form 4](/filings/0000078003-18-000080.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $62.7m | 30,146,963 | | Added +11,055,868 | | [Pfizer Inc](/funds/78003.md) | 2026-06-30 | $46.9m | 22,032,040 | | Unchanged | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $46.7m | 22,446,668 | | Added +18,650,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $39.6m | 19,025,826 | | Added +10,365,520 | | [TPG GP A, LLC](/funds/1903793.md) | 2026-06-30 | $38.9m | 18,716,306 | | Unchanged | | [Sio Capital Management, LLC](/funds/1482416.md) | 2026-06-30 | $27.7m | 13,323,431 | | New +13,323,431 | | [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $27.3m | 13,123,440 | | Added +4,743,600 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $25.3m | 12,166,636 | | Added +5,245,286 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $25.0m | 12,009,043 | | Added +10,419,213 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $21.0m | 10,087,770 | | Added +3,294,150 | ## Recent filings [All 568 filings](/companies/allo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 16:18 ET | [SCHEDULE 13D/A](/filings/0001999371-26-021654.md) | Ownership report, active investor, amended | 0001999371-26-021654 | | 2026-09-02 | 08:35 ET | [8-K](/filings/0001193125-26-379423.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-379423 | | 2026-08-12 | 16:17 ET | [10-Q](/filings/0001628280-26-056213.md) | Quarterly report, period 2026-06-30 | 0001628280-26-056213 | | 2026-08-12 | 16:12 ET | [8-K](/filings/0001628280-26-056198.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-056198 | | 2026-06-22 | 16:05 ET | [8-K](/filings/0001628280-26-044618.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001628280-26-044618 | | 2026-05-28 | 17:06 ET | [8-K](/filings/0001193125-26-245484.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-245484 | | 2026-05-13 | 16:05 ET | [10-Q](/filings/0001628280-26-034585.md) | Quarterly report, period 2026-03-31 | 0001628280-26-034585 | | 2026-05-13 | 16:03 ET | [8-K](/filings/0001628280-26-034583.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-034583 | | 2026-04-30 | 16:37 ET | [DEF 14A](/filings/0001628280-26-028948.md) | Proxy statement, period 2026-06-18 | 0001628280-26-028948 | | 2026-04-15 | 16:35 ET | [8-K](/filings/0001193125-26-157140.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-157140 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-017242.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/543901a7-56c7-45a7-9bdc-2774ffa44ac1) ## About the filer - CIK: 1737287 - Tickers: ALLO - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:28 ET. No prices; not investment advice.